---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-23-128782"
form_type: "8-K"
ticker: "BRNS"
cik: "0001828185"
company_name: "Barinthus Biotherapeutics plc."
filed_at: "2023-12-22T23:59:59+00:00"
generated_at: "2026-06-07T08:12:14.418112+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Barinthus secures up to $34.8M CEPI funding for MERS vaccine VTP-500 development

## Summary
- CEPI to provide $34.8M to advance VTP-500 through Phase II trials and develop 100,000-dose ready reserve.
- VTP-500 received EMA PRIME designation in December 2023, supporting accelerated regulatory review.
- Barinthus retains ownership of IP; will pay CEPI mid-single digit royalties on net sales and mid-double digit revenue share.
- Partnership with University of Oxford builds on ChAdOx1 platform used in Oxford-AstraZeneca COVID-19 vaccine.
- Equitable access commitments: LMICs receive vaccine at cost plus 10%; CEPI can support technology transfer.

## SEC filing metadata
- accession: 0001104659-23-128782
- form_type: 8-K
- ticker: BRNS
- cik: 0001828185
- company_name: Barinthus Biotherapeutics plc.
- filed_at: 2023-12-22T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 1.01, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1828185/000110465923128782/0001104659-23-128782-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1828185/000110465923128782/tm2333622d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-23-128782
- JSON: https://secwatch.observer/filing/0001104659-23-128782.json
- Plain text: https://secwatch.observer/filing/0001104659-23-128782.txt

## Key facts
- Material Agreements
  Barinthus Biotherapeutics plc. entered into Funding Agreement with Coalition for Epidemic Preparedness Innovations (CEPI) and the Chancellors, Masters and Scholars of the University of Oxford valued at up to $34.8 million (effective 2023-12-20).
  - Action: entry
  - Agreement: collaboration
  - Counterparty: Coalition for Epidemic Preparedness Innovations (CEPI) and the Chancellors, Masters and Scholars of the University of Oxford
  - Value: up to $34.8 million
  - Effective: 2023-12-20
  source text: On December 20, 2023, Barinthus Biotherapeutics plc (the “Company”), the Chancellors, Masters and Scholars of the University of Oxford (“Oxford,” together with the Company, the “Partners”) and the Coalition for Epidemic Preparedness Innovations (“CEPI”) entered into a Funding Agreement (the “Funding Agreement”) pursuant to which CEPI will provide funding of up to $34.8 million to the Company to advance the development of VTP-500, the Company’s vaccine candidate against Middle East Respiratory Syndrome (“MERS,” and such development activities, the “Project”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1828185/000110465923128782/0001104659-23-128782-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.